News

BUILT Biotechnologies Named Commonwealth BioAccelerator Anchor Company As Emerging Leader in DNA Manufacturing-as-Service Scales to Meet Exploding Demand

BUILT Biotechnologies, an emerging leader in DNA Manufacturing-as-a-Service, today announced its selection as an anchor company at the Commonwealth BioAccelerator, an initiative led by CvilleBioHub to strengthen Virginia’s biotechnology ecosystem. The relocation of BUILT’s headquarters to CvilleBioHub’s state-of-the-art facilities at North Fork Research Park positions the company to rapidly scale production in a new, next-generation laboratory to meet exploding demand and to grow its team by tapping Charlottesville’s talent pool.

Through its breakthrough Regenerative DNA Assembly™ process, BUILT is bridging the gap between DNA synthesis and ready-to-use DNA molecules for a growing roster of customers nationwide, from top-10 biopharma companies to university core facilities to small startups, enabling them to accelerate programs in cell and gene therapy, RNA therapeutics, and synthetic biology broadly.

The company routinely ships BUILT DNA™: sequence-perfect DNA constructs, including “unbuildable” long and complex molecules, in linear and plasmid formats. BUILT’s service provides biotech innovators with unparalleled capability, reliability, and speed, eliminating the need for in-house assembly and stepping up development timelines.

George McArthur, PhD, CEO of BUILT Biotechnologies, stated, “Our designation as an anchor company at the Commonwealth BioAccelerator validates BUILT’s rapid emergence as the partner of choice for the full range of life science operations seeking a more efficient and cost-effective way to access highest-quality, ready-built DNA. Our new North Fork lab will provide the capacity to scale and meet this pressing market need, as well as to recruit exceptional local talent and partner more closely with CvilleBioHub.”

With its expanded presence at North Fork, BUILT is also positioned to collaborate with the new Paul and Diane Manning Institute of Biotechnology at the University of Virginia, underscoring the company’s ability to serve innovators both globally and locally.

“BUILT exemplifies the kind of scale-ready company we’re proud to champion in Central Virginia,” said Nikki Hastings, PhD, Executive Director of CvilleBioHub. “As an anchor company of the Commonwealth BioAccelerator, BUILT strengthens our ecosystem by delivering the reliable, fast, and capable DNA manufacturing that growing therapeutics companies need to move from idea to impact.” The Commonwealth BioAccelerator, operated by CvilleBioHub and supported by public and private partners, provides companies with the resources and community to scale in Virginia’s biotech ecosystem.

Recent News

04/15/2026

Gov. Spanberger and Homegrown Innovator Agrospheres Celebrate Launch of Virginia’s new Biomanufacturing Facility

AgroSpheres, Inc., a Charlottesville-based agricultural biotechnology company, officially opened its first commercial biomanufacturing facility, representing a milestone for AgroSpheres and the biotech ecosystem. Speakers at the ribbon-cutting ceremony included: Virginia Governor Abigail Spanberger, AgroSpheres co-founders CEO Payam Pourtaheri and CTO Ameer Shakeel, Albemarle County Chair of the Board of Supervisors Ned Gallaway, President of the

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.